LUND, Sweden, Oct. 15, 2021 /PRNewswire/ — Immunovia AB (publ) (“Immunovia”), a diagnostic firm that develops and sells extremely correct blood checks for the early detection of most cancers, introduced at the moment that Karin Almqvist Liwendahl will be a part of Immunovia as Chief Monetary Officer (CFO).
Karin is an skilled CFO and Investor Relations skilled with a background within the telecom business and life sciences. Most just lately she has been the CFO of the medical know-how firm Dignitana. She has additionally been Monetary Advisor and CFO at Dash Bioscience and Interim CFO of Kontigo Care. Karin has 15 years’ expertise from a number of senior positions inside Telia together with Director, Company Treasury, Telia Firm, CFO of Telia Provider, Managing Director and Nation Supervisor of Telia Provider in Russia. She has additionally been Head of Investor Relations at Ericsson between 1994 and 2000. Karin holds a bachelor’s diploma from Lund College.
Present CFO Hans Liljenborg will proceed with Immunovia within the place as Finance Director.
“I’m happy to welcome Karin to our firm. Together with her deep expertise of main and creating finance features and powerful background in Investor Relations, I’m satisfied that she’s going to make an vital influence on our enterprise. As we transfer ahead, we have to proceed to strengthen our communications with the investor neighborhood, nationally and internationally. I’m additionally glad that Hans will proceed in a brand new function with Immunovia. In that means we are going to safe continuity in our finance perform”, stated Patrik Dahlen, CEO of Immunovia.
Karin will begin her project on the newest by April 1st, 2022.
For extra data, please contact:
Patrik Dahlen, CEO Immunovia
Electronic mail: firstname.lastname@example.org
Tel: +46 73 376 76 64
That is data that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The data was submitted for publication, by means of the company of the contact particular person set out above, at 13:30 CEST on October 15, 2021.
Immunovia AB is a diagnostic firm that’s creating and commercializing extremely correct blood checks for the early detection of most cancers and autoimmune illnesses primarily based on Immunovia’s proprietary take a look at platform known as IMMray™. Assessments are primarily based on antibody biomarker microarray evaluation utilizing superior machine-learning and bioinformatics to single-out a set of related biomarkers that point out a sure illness. Thus, forming a singular “illness biomarker signature”.
The corporate was based in 2007, primarily based on most cancers research and ground-breaking analysis within the Division of Immuntechnology at Lund College and CREATE Well being Most cancers Middle, Sweden.
The primary product, IMMray™ PanCan-d, is present process medical analysis in a few of the world’s largest medical research for top danger teams in pancreatic most cancers, PanFAM-1, PanSYM-1 and PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d take a look at, the primary blood-based take a look at devoted to the early detection of pancreatic most cancers in the marketplace, is obtainable as a laboratory developed take a look at (LDT) solely by means of Immunovia, Inc. For extra data see: www.immunoviainc.com. The European launch plan might be communicated through the second half of 2021.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For extra data, please go to www.immunovia.com.
This data was dropped at you by Cision http://news.cision.com
The next recordsdata can be found for obtain:
View unique content material:https://www.prnewswire.com/news-releases/immunovia-appoints-new-chief-financial-officer-301401183.html
SOURCE Immunovia AB